MingMed

MingMed (因明生物) is a Guangzhou-based biotech company founded in October 2019 that develops first-in-class drugs across ophthalmology, novel medical aesthetics, small-molecule immunology, and cell therapy . The company raised nearly $60 million in a Series A led by Gaorong Ventures in March 2021, followed by a roughly $50 million A+ round in September 2021 in which Gaorong also added to its position—bringing total 2021 fundraising to approximately $110 million . By mid-2021, its dry-AMD first-in-class ophthalmology drug had cleared U.S. IND and entered Phase I clinical trials, with CEO Zhang Yan flagging additional pipeline candidates heading into China and U.S. trials that year . The company's positioning centers on globally competitive first-in-class innovation, with what Gaorong described as a team combining "forward-looking R&D capability, highly collaborative spirit, strong execution, and broad international vision" .